Episodic migraine Overall Monthly Across Months 1 to 6 | Chronic migraine Overall Monthly Across Months 1 to 3 | |||||
---|---|---|---|---|---|---|
Pain burden individual components, LS mean (SE) | Placebo (n = 872) | Galcanezumab (n = 435) | LS Mean Difference (95% CI) | Placebo (n = 535) | Galcanezumab (n = 273) | LS Mean Difference (95% CI) |
Number of migraine headache days | −2.6 (0.2) | −4.5 (0.2)** | − 2.0 (− 2.4, − 1.6)** | − 2.7 (0.4) | −4.8 (0.4)** | − 2.1 (− 2.9, − 1.3)** |
Hours per migraine headache day | 0.1 (0.1) | −0.6 (0.1)** | − 0.7 (− 0.9, − 0.4)** | 0.1 (0.1) | −0.5 (0.2)** | − 0.7 (− 1.0, − 0.3)** |
Severity of remaining migraine headache daysa | − 0.2 (0.02) | −0.2 (0.02)* | − 0.04 (− 0.1–0.0)* | − 0.1 (0.02) | −0.2 (0.02)** | − 0.1 (− 0.1, − 0.03)** |